Literature DB >> 33649182

Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population.

Marina Penova1, Shuji Kawaguchi1, Jun-Ichirou Yasunaga2, Takahisa Kawaguchi1, Tomoo Sato3, Meiko Takahashi1, Masakazu Shimizu1, Mineki Saito4, Kunihiro Tsukasaki5, Masanori Nakagawa6, Norihiro Takenouchi7, Hideo Hara8, Eiji Matsuura9, Satoshi Nozuma9, Hiroshi Takashima9, Shuji Izumo10, Toshiki Watanabe11, Kaoru Uchimaru12, Masako Iwanaga13, Atae Utsunomiya14, Yasuharu Tabara1, Richard Paul15, Yoshihisa Yamano3, Masao Matsuoka2,16, Fumihiko Matsuda17,15.   

Abstract

HTLV-1-associated myelopathy (HAM/TSP) is a chronic and progressive inflammatory disease of the central nervous system. The aim of our study was to identify genetic determinants related to the onset of HAM/TSP in the Japanese population. We conducted a genome-wide association study comprising 753 HAM/TSP patients and 899 asymptomatic HTLV-1 carriers. We also performed comprehensive genotyping of HLA-A, -B, -C, -DPB1, -DQB1, and -DRB1 genes using next-generation sequencing technology for 651 HAM/TSP patients and 804 carriers. A strong association was observed in HLA class I (P = 1.54 × 10-9) and class II (P = 1.21 × 10-8) loci with HAM/TSP. Association analysis using HLA genotyping results showed that HLA-C*07:02 (P = 2.61 × 10-5), HLA-B*07:02 (P = 4.97 × 10-10), HLA-DRB1*01:01 (P = 1.15 × 10-9) and HLA-DQB1*05:01 (P = 2.30 × 10-9) were associated with disease risk, while HLA-B*40:06 (P = 3.03 × 10-5), HLA-DRB1*15:01 (P = 1.06 × 10-5) and HLA-DQB1*06:02 (P = 1.78 × 10-6) worked protectively. Logistic regression analysis identified amino acid position 7 in the G-BETA domain of HLA-DRB1 as strongly associated with HAM/TSP (P = 9.52 × 10-10); individuals homozygous for leucine had an associated increased risk of HAM/TSP (odds ratio, 9.57), and proline was protective (odds ratio, 0.65). Both associations were independent of the known risk associated with proviral load. DRB1-GB-7-Leu was not significantly associated with proviral load. We have identified DRB1-GB-7-Leu as a genetic risk factor for HAM/TSP development independent of proviral load. This suggests that the amino acid residue may serve as a specific marker to identify the risk of HAM/TSP even without knowledge of proviral load. In light of its allele frequency worldwide, this biomarker will likely prove useful in HTLV-1 endemic areas across the globe.
Copyright © 2021 the Author(s). Published by PNAS.

Entities:  

Keywords:  HAM/TSP; HLA; HTLV-1; genome-wide association study; proviral load

Mesh:

Substances:

Year:  2021        PMID: 33649182      PMCID: PMC7980450          DOI: 10.1073/pnas.2004199118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  34 in total

1.  HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes.

Authors:  S Yashiki; T Fujiyoshi; N Arima; M Osame; M Yoshinaga; Y Nagata; M Tara; K Nomura; A Utsunomiya; S Hanada; K Tajima; S Sonoda
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-20       Impact factor: 2.205

2.  HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma.

Authors:  K Usuku; S Sonoda; M Osame; S Yashiki; K Takahashi; M Matsumoto; T Sawada; K Tsuji; M Tara; A Igata
Journal:  Ann Neurol       Date:  1988       Impact factor: 10.422

3.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

4.  The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I.

Authors:  J E Kaplan; M Osame; H Kubota; A Igata; H Nishitani; Y Maeda; R F Khabbaz; R S Janssen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

6.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

7.  Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Yoshihisa Yamano; Tomoo Sato
Journal:  Front Microbiol       Date:  2012-11-09       Impact factor: 5.640

8.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis.

Authors:  Soumya Raychaudhuri; Cynthia Sandor; Eli A Stahl; Jan Freudenberg; Hye-Soon Lee; Xiaoming Jia; Lars Alfredsson; Leonid Padyukov; Lars Klareskog; Jane Worthington; Katherine A Siminovitch; Sang-Cheol Bae; Robert M Plenge; Peter K Gregersen; Paul I W de Bakker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330

9.  Phase-defined complete sequencing of the HLA genes by next-generation sequencing.

Authors:  Kazuyoshi Hosomichi; Timothy A Jinam; Shigeki Mitsunaga; Hirofumi Nakaoka; Ituro Inoue
Journal:  BMC Genomics       Date:  2013-05-28       Impact factor: 3.969

10.  Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net).

Authors:  Ariella L G Coler-Reilly; Naoko Yagishita; Hiroko Suzuki; Tomoo Sato; Natsumi Araya; Eisuke Inoue; Ayako Takata; Yoshihisa Yamano
Journal:  Orphanet J Rare Dis       Date:  2016-05-25       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.